Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02309177
Title Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Celgene Corporation
Indications

lung non-small cell carcinoma

Her2-receptor negative breast cancer

pancreatic adenocarcinoma

Therapies

Carboplatin

Gemcitabine

Nab-paclitaxel + Nivolumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.